文献速递慢性静脉疾病

氰基丙烯酸酯栓塞功能不全穿通静脉治疗CEAP-6期患者的单中心临床经验

Single-center clinical experience of cyanoacrylate embolization method for incompetent perforating veins in treating CEAP-6 patients.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2024-07-01

本研究回顾性纳入2018至2021年因静脉性腿部溃疡接受氰基丙烯酸酯栓塞功能不全穿通静脉的187例CEAP-6期患者,术后12个月87.1%患者穿通静脉闭合并溃疡完全愈合,溃疡直径和静脉临床严重程度量表评分显著下降,无术后感觉异常或深静脉血栓形成。

要点

  • 术后12个月87.1%患者功能不全穿通静脉闭合并静脉性腿部溃疡完全愈合。
  • 术前溃疡直径由7.20±3.48 cm²降至术后0.28±0.77 cm²(P<.001)。
  • 糖尿病使穿通静脉未闭合可能性增加3.4倍(95%CI 1.11-10.44;P=.032)。

核心结论

  • 本研究表明,氰基丙烯酸酯栓塞功能不全穿通静脉在CEAP-6期患者中有效、安全且并发症率低。
  • 研究结果支持氰基丙烯酸酯栓塞穿通静脉可能是治疗静脉性腿部溃疡的有价值选择。

研究设计与样本

  • 回顾性综述2018至2021年因静脉性腿部溃疡接受氰基丙烯酸酯栓塞功能不全穿通静脉的187例患者。
  • 术后12个月评估穿通静脉闭合、溃疡直径和静脉临床严重程度量表。
  • 采用受试者工作特征分析基于术前溃疡直径和穿通静脉平均直径估计术后穿通静脉未闭合概率,并采用单因素和多因素二元逻辑回归分析识别与穿通静脉不完全闭合相关的危险因素。

主要发现

  • 术后12个月87.1%患者功能不全穿通静脉闭合,导致静脉性腿部溃疡完全愈合。
  • 术前溃疡直径由7.20±3.48 cm²显著降至术后0.28±0.77 cm²(P<.001)。
  • 平均治疗3.5±1.01条穿通静脉,直径为4.09±0.41 mm;无术后感觉异常或深静脉血栓形成发生。
  • 术前静脉临床严重程度量表评分由17.85±3.06显著降至术后8.03±3.53(P<.001)。
  • 穿通静脉未闭合患者术前溃疡直径(13.77±1.78 cm²)大于穿通静脉闭合患者(6.24±2.47 cm²;P<.001),且穿通静脉平均直径在未闭合患者(4.45±0.41 mm)中也大于闭合患者(4.04±0.38 mm;P<.001)。

关键数值与推荐

  • 术前溃疡直径截断值11.25 cm²预测术后穿通静脉未闭合可能性的敏感度、特异度和准确度均为100%。
  • 术前穿通静脉平均直径截断值4.15 mm的敏感度、特异度和准确度分别为66.7%、79.1%和77.5%。
  • 糖尿病使功能不全穿通静脉保持开放的可能性增加3.4倍(95%CI 1.11-10.44;P=.032)。
  • 穿通静脉平均直径每增加1 mm使该可能性增加9.36倍(95%CI 3.47-25.29;P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The most severe form of chronic venous insufficiency includes venous leg ulcers in the CEAP-6 stage. The aim of this study is to evaluate the relationship between incompetent perforator veins occluding with cyanoacrylate and closure of perforator veins and healing of venous leg ulcers in patients at the CEAP-6 stage. METHODS: A total of 187 patients who underwent cyanoacrylate application to incompetent perforator veins due to venous leg ulcers from 2018 to 2021 were retrospectively reviewed. Twelve months after the procedure, patients were evaluated for perforator vein closure, ulcer diameter, and Venous Clinical Severity Scale. Receiver operating characteristic analysis was used to estimate the probability of postoperative nonocclusion of the perforating vein based on the preoperative ulcers' diameters and the perforating veins' mean diameters. Univariate and multivariate binary logistic regression analyses were conducted to identify the risk factors associated with incomplete closure of the perforating vein. RESULTS: At the 12 months, 87.1% of patients experienced incompetent perforator veins closure, leading to complete healing of venous leg ulcers. Preoperative ulcer diameter significantly decreased from 7.20 ± 3.48 cm2 to 0.28 ± 0.77 cm2 after the procedure (P < .001). On average, 3.5 ± 1.01 perforating veins were treated, with a diameter of 4.09 ± 0.41 mm. No postoperative paresthesia or deep vein thrombosis occurred. Preoperative Venous Clinical Severity Scale scores decreased significantly from 17.85 ± 3.06 to 8.03 ± 3.53 postoperatively (P < .001). Patients with nonoccluded perforating veins had larger preoperative ulcer diameters (13.77 ± 1.78 cm2) than those with occluded perforating veins (6.24 ± 2.47 cm2; P < .001). The mean perforating vein diameter was also larger in nonoccluded perforating veins patients (4.45 ± 0.41 mm) than in occluded perforating veins patients (4.04 ± 0.38 mm; P < .001). The sensitivity, specificity, and accuracy of the preoperative ulcer diameter cutoff point of 11.25 cm2 for the possibility of postoperative nonocclusion of perforating veins were 100% each. In contrast, those for the preoperative mean perforating vein diameter cutoff point of 4.15 mm were determined as 66.7%, 79.1%, and 77.5%, respectively. The presence of diabetes mellitus increased the likelihood of incompetent perforator veins, remaining open by 3.4 times (95% confidence interval: 1.11-10.44; P = .032), whereas a 1 mm larger mean perforating vein diameter increased this likelihood by 9.36 times (95% confidence interval: 3.47-25.29; P < .001). CONCLUSIONS: This study demonstrates that occlusion of incompetent perforator veins with cyanoacrylate is effective, safe, and associated with low complication rates in CEAP-6 patients. The findings support that cyanoacrylate occlusion of perforator veins may be a valuable option in the treatment of venous leg ulcers.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Türkmen U. Single-center clinical experience of cyanoacrylate embolization method for incompetent perforating veins in treating CEAP-6 patients. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38960130. doi:10.1016/j.jvsv.2024.101939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。